VANCOUVER, Nov. 1 /PRNewswire-FirstCall/ - AnorMED Inc. announced today that it has received approval to list its common shares on the American Stock Exchange (AMEX) under the symbol AOM. In connection with its application to AMEX, the Company filed a Registration Statement on Form 40-F with the United States Securities and Exchange Commission (SEC) to register its common shares pursuant to Section 12(b) of the Securities Exchange Act of 1934. The Company’s registration statement has not yet become effective and the AMEX approval is conditional on the registration statement being declared effective.
AnorMED’s common shares trade on The Toronto Stock Exchange under the symbol AOM. There are currently approximately 31.8 million shares outstanding (35.3 million shares fully diluted).
AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. Information on AnorMED is available on the Company’s website: www.anormed.com.
Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update any forward-looking statements as conditions change. Investors are referred to the discussion of the risks factors associated with the Company’s business contained in the Company’s Annual Information Form filed with securities regulatory authorities dated June 23, 2005.
Kim Nelson, Ph.D. W.J. (Bill) Adams, C.A., Manager, Investor Relations Chief Financial Officer Tel: 604-532-4654 Tel: 604-530-1057 Cell: 604-614-2886 Email: info@anormed.com Email: knelson@anormed.com
AnorMED Inc.
CONTACT: Kim Nelson, Ph.D., Manager, Investor Relations, Tel: (604)532-4654, Cell: (604) 614-2886, Email: knelson@anormed.com; W.J. (Bill)Adams, C.A., Chief Financial Officer, Tel: (604) 530-1057, Email:info@anormed.com